Oncology (A) fever-range WBH
1. Clinical studies using heckel WBH systems
Zschaeck S, Weingärtner J, Ghadjar P, Wust P, Mehrhof F, Kalinauskaite G, Ehrhardt VH, Hartmann V, Tinhofer I, Heiland M, Coordes A, Kofla G, Budach V, Stromberger C, Beck M:
Fever range whole body hyperthermia for re-irradiation of head and neck squamous cell carcinomas: Final results of a prospective study
Oral Oncol. 2021 Feb 21;116:105240. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/33626457/
Rogasch J, Beck M, Stromberger C, Hofheinz F, Ghadjar P, Wust P, Budach V, Amthauer H, Tinhofer I, Furth C, Walter-Rittel TC, Zschaeck S:
PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study
F1000Res. 2020 Nov 19;9:1350
OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970429/
Kleef R, Nagy R, Baierl A, Bacher V, Bojar H, McKee DL, Moss R, Thoennissen NH, Szász M, Bakacs T
Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution
Cancer Immunol Immunother. 2020
OPEN ACCESS: https://link.springer.com/article/10.1007/s00262-020-02751-0
Kobayashi Y, Itoa Y, Ostapenko VV, Sakai M, Matsushita N, Imai K, Shimizu K, Aruga A,Tanigawa K:
Fever-range whole-body heat treatment stimulates antigen-specificT-cell responses in humans
Immunology Letters 162 (2014) 256–261
https://www.ncbi.nlm.nih.gov/pubmed/25256774
Sulyok I, Fleischmann E, Stift A, Roth G, Lebherz-Eichinger D, Kasper D, Spittler A, Kimberger O:
Effect of preoperative fever-range whole-body hyperthermia on immunological markers in patients undergoing colorectal cancer surgery
Br J Anaesth. 2012 Nov;109(5):754-61
OPEN ACCESS https://academic.oup.com/bja/article/109/5/754/305182/Effect-of-preoperative-fever-range-whole-body
Bull JM, Scott GL, Strebel FR, Nagle VL, Oliver D, Redwine M, Rowe RW, Ahn CW, Koch SM:
Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol.
Int J Hyperthermia. 2008 Dec;24(8):649-62
https://www.ncbi.nlm.nih.gov/pubmed/18608594
Kraybill WG, Olenki T, Evans SS, Ostberg JR, O'Leary KA, Gibbs JF, Repasky EA:
A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: correlation with mouse models.
Int J Hyperthermia. 2002 May-Jun;18(3):253-66
https://www.ncbi.nlm.nih.gov/pubmed/12028640
2. Clinical case reports using heckel WBH systems
Kleef R, Bacher V, Nagy R, Reisegger P, Bakacs T:
Complete Remission of Vocal Cord Cancer Treated With Low-Dose Ipilimumab Plus Nivolumab Combined With Interleukin-2 and Hyperthermia
Cureus. 2021 Apr 15;13(4):e14500. doi: 10.7759/cureus.14500.
OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123238/
Kleef R, Moss R, Szasz AM, Bohdjalian A, Bojar H, Bakacs T:
Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2
Integr Cancer Ther. 2018 Dec; 17(4): 1297–1303.
OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247552/
Rich LJ, Winslow TB, Alberico RA, Repasky EA, Seshadri M, Singh AK:
Enhanced tumour perfusion following treatment with water-filtered IR-A radiation to the thorax in a patient with head and neck cancer.
Int J Hyperthermia. 2016 Aug;32(5):539-42, LETTER TO THE EDITOR
https://www.ncbi.nlm.nih.gov/pubmed/27150820
Kleef R, Kekic S, Ludwig N:
Successful Treatment of Advanced Ovarian Cancer with Thermochemotherapy and Adjuvant Immune Therapy
Case Rep Oncol 2012;5:212–215
OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369243/
3. Pre-clinical studies
Rowe RW, Strebel FR, Proett JM, Deng W, Chan D, He G, Siddik ZH, Bull JMC:
Fever-Range Whole-body Thermotherapy Combined With Oxaliplatin: A Curative Regimen in a Preclinical Breast Cancer Model
Int J Hyperthermia. 2010; 26(6): 565–576
OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045248/
4. Reviews
Bull JMC:
A review of immune therapy in cancer and a question: can thermal therapy increase tumor response?
Int J Hyperthermia. 2018 Sep;34(6):840-852.
OPEN ACCESS: https://www.tandfonline.com/doi/pdf/10.1080/02656736.2017.1387938?needAccess=true
Yagawa Y, Tanigawa K, Kobayashi Y, Yamamoto M:
Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery.
J Cancer Metastasis Treat 2017;3:218-30
OPEN ACCESS: http://jcmtjournal.com/article/view/2272
Repasky EA, Evans SS, Dewhirst M:
Temperature Matters! And Why it Should Matter to Tumor Immunologists.
Cancer Immunol Res. 2013 Oct 1; 1(4)
OPEN ACCESS: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904378/
Faghihi Moghadam F, Bakhshandeh M, Sahinbas H:
Hyperthermia: A Neoadjuvant Therapeutic Approach in Cancer Treatment
CANCERPRESS Vol. 3, No.1, March, 2017
OPEN ACCESS: https://www.semanticscholar.org/paper/Hyperthermia%3A-A-Neoadjuvant-Therapeutic-Approach-in-Moghadam-Bakhshandeh/bddde59d4cf9518d10b83029b7ec29ab895d75e7
5. Books, book chapters
Zschaeck S, Beck M:
Whole-Body Hyperthermia in Oncology: Renaissance in the Immunotherapy Era?
In: Water-filtered Infrared A (wIRA) Irradiation (Ed.: P. Vaupel), pp. 107-115. Springer Nature Switzerland, Cham. DOI: 10.1007/978-3-030-92880-3_8
OPEN ACCESS https://link.springer.com/content/pdf/10.1007%2F978-3-030-92880-3_8
Tanigawa K, Ito Y, Kobayashi Y:
Effects of Fever-Range Hyperthermia on T Cell-Mediated Immunity: Possible Combination of Hyperthermia and T Cell-Based Cancer Immunotherapy
in: S. Kokura et al. (eds.), Hyperthermic Oncology from Bench to Bedside, Springer Science+Business Media Singapore 2016
https://link.springer.com/chapter/10.1007/978-981-10-0719-4_31
Rowe-Horwege W:
Hyperthermia, Systemic
in Enceclopedia of Medical Devices and Instrumentation, Second Edition, 2006 John Wiley & Sons, Inc.
https://onlinelibrary.wiley.com/doi/10.1002/0471732877.emd138
6. Congress abstracts:
Kleef R, Nagy R, Bacher V, Bakacs T, Lausch T, McKee D, Moss R, Bojar H, Thoennissen N:
Low-dose checkpoint inhibitors with hyperthermia and IL-2 are safe and effective in stage IV cancer with unfavourable immunological profile (MSI low, PD-L1 under 1%, TMB low) – A single-institution experience from 2015 to 2020
The 7th leading International Cancer Immunotherapy Conference in Europe, 2–4 October 2020, virtual conference, P08.01
J Immunother Cancer 2020;8(Suppl 2):A1–A67
PDF Download
Kleef R, Nagy R, Bohdjalian A, Bacher V, Kekic A, Kekic S, McKee D, Bojar H, Moss R:
Complete response of stage IV pancreatic cancer combining dose adapte d checkpoint inhibitors with interleukin 2 (IL 2) and fever range hyperthermia
Poster - CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE, 25-28 Sep 2019, Paris
PDF Download
Kleef R:
Coley remembered – back to the roots. Fevertherapy of cancer in the light of modern immunology.
Abstract - Medizinische Woche Baden-Baden 03.10.-03.11.2019
PDF Download
Kleef R, Nagy R, Bohdjalian A, Bacher V, Wychera A, Kekic S, McKee D, Bojar H, Moss R:
Complete response of stage IV pancreatic cancer combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia
The 6th Leading International Cancer Immunotherapy Conference in Europe / European Journal of Cancer 110 (2019) S22
https://www.ejcancer.com/article/S0959-8049(19)30099-1/fulltext
Wey S:
14 years fever-range whole body hyperthermia in adjuvant recurrence prophylaxis of breast cancer.
ESHO 2018 Berlin, P 12
https://link.springer.com/content/pdf/10.1007%2Fs00066-018-1295-1.pdf , p. 495
Wey S:
Secondary and tertiary recurrence prevention with fever range whole-body hyperthermia in (metastatic) malignant melanoma.
ESHO 2018 Berlin, P 13
https://link.springer.com/content/pdf/10.1007%2Fs00066-018-1295-1.pdf , p. 496
Kleef R, Bojar H, Moss R, Stix A, Bohdjalian A, Bacher V, Nagy R, McKee D:
Exogenous and endogenous hyperthermia combining lowdose checkpoint inhibitors with interleukin-2 (IL-2) and fever range whole body and local regional hyperthermia in stage IV cancer.
ESHO 2018 Berlin, P 35
https://link.springer.com/content/pdf/10.1007%2Fs00066-018-1295-1.pdf , p. 504
Pinto J, Ferreira A, Ferreira C, Cruz A, Pinto M:
Fever-range whole body hyperthermia with concomitant capecitabine in third line therapy for BRCA mutated metastatic breast cancer.
ESHO 2018 Berlin, P 38
https://link.springer.com/content/pdf/10.1007%2Fs00066-018-1295-1.pdf , p. 506
Kleef R, Bohdjalian A, McKee D, Moss RW:
Complete response of stage IIIB esophageal cancer combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia.
4th ImmunoTherapy of Cancer Conference, Prague, Czech Republic. 20–22 March 2017, A39
J Immunotherapy Cancer 5, 12 (2017).
https://jitc.biomedcentral.com/articles/10.1186/s40425-017-0219-4
Kleef R:
Low-dose checkpoint inhibitor therapy with interleukin-2 (IL-2) and fever range hyperthermia in stage IV cancer: a retrospective analysis with single case presentations
ESHO 2017 21-23 June Athens, Greece, Abstracts OP-10
ESHO2017 ABSTRACTBOOK , p. 65
Kleef R, Bohdjalian A, McKee D, Moss RW:
Complete response of stage IIIB esophageal cancer combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia.
Journal for ImmunoTherapy of Cancer 2017, 5(Suppl 1):12 DOI 10.1186/s40425-017-0219-4
https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-017-0219-4 , A39, p.15
Kleef R, Moss RW, Szasz AM, Bohdjalian A, Bakacs T:
Near complete remission of pulmonary metastases in triple negative breast cancer (TNBC) using low-dose immune checkpoint (IC) inhibitors with high dose (HD) interleukin-2 (IL-2) and fever range hyperthermia
EJC, Vol55, Suppl.1, March 2016; 3rd Immunotherapy of Cancer Conference 21–23 March, 2016, Munich/Germany
http://meetinglibrary.asco.org/record/127689/abstract
Oncology (B) extreme WBH
1. Clinical studies using heckel WBH systems
Changlin Zhao , Congqi Dai, Xiaoyin Chen:
Whole body hyperthermia combined with intraperitoneal chemotherapy for the treatment of stage IV advanced gastric cancer
Int.J.Hyperthermia, December 2012; 28(8): 735-741
https://www.ncbi.nlm.nih.gov/pubmed/23113543
Douwes F, Bogovic J, Douwes O, Migeod F, Grote C:
Whole body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer
Int J Clin Oncol. 2004 Apr;9(2):85-91
https://www.ncbi.nlm.nih.gov/pubmed/15108039
Gaworek J, Mayer CT:
Systemische Ganzkörperhyperthermie in der Onkologie: Tödliche Hitze für Tumorzellen
[Systemic whole body hyperthermia in oncology: fatal heat for tumor cells].
Pflege Z. 2003 Jan;56(1):15-8
[ARTICLE IN GERMAN] http://www.daryan.de/admin/download/file_150.pdf
Reichel M, Scheeren TWL, Douwes O, Konrad RM:
Tiefe intravenöse Analgosedierung zur extremen Ganzkörperhyperthermie in Kombination mit Chemotherapie
[Deep intravenous analgosedation for extreme whole-body hyperthermia in combination with chemotherapy]
Forum Komplementäre Onkologie & Forum Immunologie, 3/2004, 4-8
[ARTICLE IN GERMAN] OPEN ACCESS http://www.rug.nl/research/portal/files/38850130/2004_Tiefe_intravenoese_Analgosedierung_zur_extremen_Ganzkoerperhyperthermie_in_Kombination_mit_Chemotherapie.pdf
|
